Larazotide May Speed Recovery in Children With Multisystem Inflammatory Syndrome

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 6, 2025.

via HealthDay

WEDNESDAY, Aug. 6, 2025 -- Treatment of multisystem inflammatory syndrome in children (MISC), a postacute sequela of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), with larazotide speeds resolution of gastrointestinal symptoms and clearance of spike antigen, according to a study published online July 30 in Science Translational Medicine.

According to Lael M. Yonker, M.D., from Massachusetts General Hospital in Boston, and colleagues, a potential role for viral spike protein translocated via zonulin-mediated trafficking from gastrointestinal reservoirs of SARS-CoV-2 into the circulation has been suggested for treatment of postacute sequelae of COVID-19 (PASC). Yonker and colleagues reported the results of a phase 2a randomized trial testing the zonulin antagonist larazotide in 12 children with MISC (median age, 5.7 years). Children were enrolled during acute MISC hospitalization and were treated four times daily with adjuvant larazotide therapy for three weeks. Twenty-four weeks of follow-up was conducted for safety monitoring.

The researchers found no reports of larazotide-related adverse events. They found a correlation of concentration of SARS-Cov-2 spike protein antigen in blood samples with inflammatory markers, including interferon-γ and interleukin-6, and with gastrointestinal symptoms. Faster resolution of gastrointestinal symptoms, faster clearance of spike antigen, and a faster return to usual activities were seen for children treated with larazotide.

"Whereas the study here targeted MISC, evidence suggests a continuum of pathogenesis across other forms of postacute sequelae of COVID-19, and, therefore, larazotide should be considered as an adjuvant therapy targeting gastrointestinal symptoms in other forms of PASC," the authors write.

Several authors disclosed ties to the biopharmaceutical industry; several authors are coinventors on a patent relating to zonulin antagonists for treatment of MISC.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-07 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords